Overview

A Phase III Clinical Study to Compare the Efficacy and Safety of DA-3801 and That of Gonal-F®

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
open label, active-controlled, randomized, parallel group, comparative study.
Phase:
Phase 3
Details
Lead Sponsor:
Dong-A Pharmaceutical Co., Ltd.
Dong-A ST Co., Ltd.